Back to search results

ALPINE: Maintenance Letrozole/Abemaciclib

Abroad (travel likely)RecruitingPHASE2

Conditions

Endometrial Cancer · Recurrent Endometrial Cancer · TP53

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

    Contact: Study coordinator (Meghan Shea, MD) · mshea4@bidmc.harvard.edu · 617-667-3723
    Contact: Principal Investigator (Meghan Shea, MD)

  • Brigham and Women's Hospital, Boston, Massachusetts, United States

    Contact: Study coordinator (Panagiotis Konstantinopoulos, MD, PhD) · Panagiotis_Konstantinopoulos@dfci.harvard.edu · 617-632-2334
    Contact: Principal Investigator (Panagiotis Konstantinopoulos, MD, PhD)

  • Dana-Farber Cancer Institute, Boston, Massachusetts, United States

    Contact: Study coordinator (Panagiotis Konstantinopoulos, MD, PhD) · Panagiotis_Konstantinopoulos@dfci.harvard.edu · 617-632-2334
    Contact: Principal Investigator (Panagiotis Konstantinopoulos, MD, PhD)

  • Dana-Farber Cancer Institute at Foxborough, Foxborough, Massachusetts, United States

  • Dana-Farber Cancer Institute at Milford, Milford, Massachusetts, United States

  • Dana-Farber Cancer Institute at South Shore Hospital, Weymouth, Massachusetts, United States

    Contact: Study coordinator (Meredith Faggen, MD) · meredith_faggen@dfci.harvard.edu · 781-624-4800
    Contact: Principal Investigator (Meredith Faggen, MD)
Study leads

  • Panagiotis Konstantinopoulos, MD, PhD

    Principal Investigator

    Dana-Farber Cancer Institute

View source on ClinicalTrials.gov(opens in a new tab)